LEKOVI PROTIV BOLA SA POSEBNIM OSVRTOM NA TRAMADOL
Sažetak
Bol predstavlja značajan medicinski i socijalni problem jer utiče na svakodnevno funkcionisanje, kao i na do psihičko, emocionalno i socijalno blagostanje, uzrokujući značajne zdravstvene i ekonomske posledice. Kontrola bola jedan je od osnovnih ciljeva savremene medicine, a lekovi koji se koriste u tu svrhu nazivaju se analgetici. Ne postoji jedinstveni lek koji odgovara svakoj vrsti bola, zbog čega je individualni pristup svakom pacijentu od ključnog značaja za lečenje. Cilj je dokazati da upotreba tramadola u otklanjanju i ublažavanju bola, uz jasno definisane indikacije, strogo kontrolisan način primene, precizno određenu dozu i ograničeno vreme primene, može predstavljati efikasnu terapijsku opciju za lečenje umerenog i umereno jakog bola kada su lekovi prvog reda nedovoljno efikasni ili kontraindikovani. „Lek istovremeno predstavlja i lek i otrov!” Kada se koristi prema indikacijama i u skladu sa uputstvom za primenu, ispoljava svoje pozitivno dejastvo, dok u slučaju nepoštovanja indikacija, terapiskih doza, vremenskog intervala i dužine trajanja terapije može ispoljiti negativne efekte. Zdravstveni radnici su u obavezi da procene rizik od zavisnosti pre započinjanja terapije.
Reference
LITERATURA
National Academies of Sciences, Engineering, and Medicine. Compounded Topical Pain Creams: Review of Select Ingredients for Safety, Effectiveness, and Use. Schwinn DA, Jackson LM, editors. Washington (DC): The National Academies Press; 2020. doi: 10.17226/25689.
Lemke TL, Williams DA, editors. Foye's Principles of Medicinal Chemistry. 5th ed. Baltimore (MD): Lippincott Williams & Wilkins; 2002. Chapter 19, Opioid analgesics; p. 453-78.
Brunton LL, Lazo JS, Parker KL, editors. Goodman & Gilman's The Pharmacological Basis of Therapeutics. 11th ed. New York: McGraw-Hill; 2006. Chapter 26, Analgesic-antipyretic agents; pharmacotherapy of gout; p. 671-716.
Ross JR, Riley J, Quigley C, Welsh KI. Clinical pharmacology and pharmacotherapy of opioid switching in cancer patients. Oncologist. 2006;11(7):765-73. doi: 10.1634/theoncologist.11-7-765.
Elliott KJ, Brodsky M, Hynansky A, Foley KM, Inturrisi CE. Dextromethorphan shows efficacy in experimental pain (nociception) and opioid tolerance. Neurology. 1995;45(12 Suppl 8):S66-8.
Ruscitto A, Smith BH, Guthrie B. Changes in opioid and other analgesic use 1995-2010: repeated cross-sectional analysis of dispensed prescribing for a large geographical population in Scotland. Eur J Pain. 2015;19(1):59-66. doi: 10.1002/ejp.520.
Araujo AM, Gómez M, Pascual J, Castañeda M, Pezonaga L, Borque JL. [Treatment of pain in the oncology patient]. An Sist Sanit Navar. 2004;27 Suppl 3:63-75.
Maltoni M, Scarpi E, Modonesi C, Passardi A, Sansoni E, Ruscelli P, et al. A validation study of the WHO analgesic ladder: a two-step vs three-step strategy. Support Care Cancer. 2005;13(11):888-94.
Varagić VM, Milošević MP. Farmakologija. 23. prerađeno i dopunjeno izd. Beograd: Elit Medica; 2012.
Raffa RB, Friderichs E, Reimann W, Shank RP, Codd EE, Vaught JL, et al. Complementary and synergistic antinociceptive interaction between the enantiomers of tramadol. J Pharmacol Exp Ther. 1992;260(1):275-85.
Albrecht E, Pereira P, Bazon V, Berger M, Wegrzyn J, Antoniadis A, et al. The relationship between postoperative opioid analgesia and sleep apnea severity in patients undergoing hip arthroplasty: a randomized, controlled, triple-blinded trial. Nat Sci Sleep. 2022;14:303-10. doi: 10.2147/NSS.S353342.
Crush J, Levy N, Knaggs RD, Lobo DN. Misappropriation of the 1986 WHO analgesic ladder: the pitfalls of labeling opioids as weak or strong. Br J Anaesth. 2023;130(1):e16-e17. doi: 10.1016/j.bja.2022.09.025.
VanAtta C, Perry LA, Crase A, Swierz A, Wenzinger S. Guidelines for the treatment of osteoarthritis. Findlay (OH): University of Findlay; 2023.
Lintz W, Beier H, Gerloff J. Bioavailability of tramadol after i.m. injection in comparison to i.v. infusion. Int J Clin Pharmacol Ther. 1999;37(4):175-83.
Dhesi M, Maldonado KA, Patel P, Maani CV. Tramadol. [Updated 2024 Feb 20]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024.
Gong L, Stamer UM, Tvetkov MV, Altman RB, Klein TE. PharmGKB summary: tramadol pathway. Pharmacogenet Genomics. 2014;24(7):374-80. doi: 10.1097/FPC.0000000000000057.
Dean L, Kane M. Tramadol Therapy and CYP2D6 Genotype. In: Pratt VM, Scott SA, Pirmohamed M, et al., editors. Medical Genetics Summaries [Internet]. Bethesda (MD): NCBI; 2015.
Grond S, Sablotzki A. Clinical pharmacology of tramadol. Clin Pharmacokinet. 2004;43(13):879-923. doi: 10.2165/00003088-200443130-00004.
Quinlan J, Macintyre PE. The pitfalls of labeling opioids as weak or strong. Comment on Br J Anaesth 2022;129:137-42. Br J Anaesth. 2022;129(6):e150-e153.
Radbruch L, Grond S, Lehmann KA. A risk-benefit assessment of tramadol in the management of pain. Drug Saf. 1996;15(1):8-29. doi: 10.2165/00002018-199615010-00002.
Dolan E, Delanty N. Tramadol use and risk of seizures: A report of two cases and a review of recent literature. Seizure. 2008;17(3):284-8.
Bakr MH, Radwan E, Shaltout AS, Farrag AA, Mahmoud AR, Abd-Elhamid TH, et al. Chronic exposure to tramadol induces cardiac inflammation and endothelial dysfunction in mice. Sci Rep. 2021;11:18772. doi:10.1038/s41598-021-98206-2.
Generes WM, Thomas S. Tramadol withdrawal symptoms, timeline and detox treatment. American Addiction Centers [Internet]. Updated 2025 Jan 17. Available from: https://americanaddictioncenters.org/opioids/tramadol/withdrawal-detox
Brackett CD, Duncan M, Wagner JF, Fineberg L, Kraft S. Multidisciplinary treatment of opioid use disorder in primary care using the collaborative care model. J Am Board Fam Med. 2022;35(1):240-244.